How much does timing matter in drug development? Does being first, second, or fifth into a therapeutic space really change your company’s fortunes? And what can past examples tell us about smarter portfolio decisions today?

Join pharma strategist Mark Tillotson as he unpacks:

• The relationship between order of entry into R&D programs and long-term company value.
• Case studies where herding paid off – and where it destroyed value.
• Practical implications for how pharma and biotech should approach pipeline and portfolio choices.

Mark will share a fresh analysis powered by recent data – made feasible by AcademicLabs.com – to explore how companies can avoid the risks of herd behavior and redirect resources to higher-impact opportunities.

At the end, you’ll also get a quick look at how you can try the platform and the AI yourself with a complimentary two-week trial.